Gut and Liver 2010; 4(4): 514-517 https://doi.org/10.5009/gnl.2010.4.4.514 A Planned Prospective, Randomized, Placebo-Controlled Multicenter Trial Assessing the Effect of Helicobacter pylori Eradication on the Healing of Iatrogenic Ulcer after Endoscopic Resection of Gastric Neoplasm
Author Information
Sang Gyun Kim*, Ho June Song, Il Ju Choi, Joo Young Cho§, Hwoon-Yong Jung, Bora Keum, Jae Hee Cheon, Yong Chan Lee, Jae Gyu Kim**, Sue K. Park††, Byung Joo Park††, and Hyun Chae Jung*; Korean College of Helicobacter and Upper Gastrointestinal Research
*Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Department of Internal Medicine, Ulsan University College of Medicine, Seoul, Center for Gastric Cancer, National Cancer Center, Goyang, §Department of Internal Medicine, Soonchunhyang University College of Medicine, Seoul, Department of Internal Medicine, Korea University College of Medicine, Seoul, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, **Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, ††Department of Preventive Medicine, Seoul National University College of Medicine and Medical Research Collaboration Center, Seoul National University College of Medicine and Seoul National University Hospital, Seoul; Korean College of Helicobacter and Upper Gastrointestinal Research, Seoul, Korea

Hyun Chae Jung
© The Korean Society of Gastroenterology, the Korean Society of Gastrointestinal Endoscopy, the Korean Society of Neurogastroenterology and Motility, Korean College of Helicobacter and Upper Gastrointestinal Research, Korean Association the Study of Intestinal Diseases, the Korean Association for the Study of the Liver, Korean Pancreatobiliary Association, and Korean Society of Gastrointestinal Cancer. All rights reserved.

Abstract
Background/Aims: Helicobacter pylori eradication may facilitate the healing of iatrogenic ulcer after endoscopic resection of gastric neoplasm. This study involved designing a randomized, double-blinded, placebo-controlled, multicenter trial, performed by the Korean College of Helicobacter and Upper Gastrointestinal Research and the Medical Research Collaboration Center, Seoul National University Hospital. Methods: We intend to enroll up to 232 patients H.- pylori-positive patients who have gastric adenoma or early gastric cancer after endoscopic resection. The enrolled patients are being randomly allocated to the H.-pylori-eradication-plus-proton-pump-inhibitor group or the placebo-plus-proton-pump-inhibitor group based on their histology results and the size of the resected specimen. After random allocation, the iatrogenic ulcer size and stage are evaluated at 4- and 8-week follow-ups (with a window of ±7 days). The primary end point is the healing rate of the ulcer by stage, and the secondary end point is the rate of ulcer size reduction, relief rate from ulcer-related symptoms, and adverse-event rates. Results: More than 90% of the target subjects have already been enrolled into the study and are receiving ongoing periodic monitoring by the Medical Research Collaboration Center. Conclusions: Completion of the study should reveal whether H. pylori eradication can facilitate the healing of ulcer after endoscopic resection in Korea. (Gut Liver 2010;4:514-517)
Keywords: Helicobacter pylori; Iatrogenic ulcer; Endoscopic resection; Eradication; Medical Research Collaboration Center
Abstract
Background/Aims: Helicobacter pylori eradication may facilitate the healing of iatrogenic ulcer after endoscopic resection of gastric neoplasm. This study involved designing a randomized, double-blinded, placebo-controlled, multicenter trial, performed by the Korean College of Helicobacter and Upper Gastrointestinal Research and the Medical Research Collaboration Center, Seoul National University Hospital. Methods: We intend to enroll up to 232 patients H.- pylori-positive patients who have gastric adenoma or early gastric cancer after endoscopic resection. The enrolled patients are being randomly allocated to the H.-pylori-eradication-plus-proton-pump-inhibitor group or the placebo-plus-proton-pump-inhibitor group based on their histology results and the size of the resected specimen. After random allocation, the iatrogenic ulcer size and stage are evaluated at 4- and 8-week follow-ups (with a window of ±7 days). The primary end point is the healing rate of the ulcer by stage, and the secondary end point is the rate of ulcer size reduction, relief rate from ulcer-related symptoms, and adverse-event rates. Results: More than 90% of the target subjects have already been enrolled into the study and are receiving ongoing periodic monitoring by the Medical Research Collaboration Center. Conclusions: Completion of the study should reveal whether H. pylori eradication can facilitate the healing of ulcer after endoscopic resection in Korea. (Gut Liver 2010;4:514-517)
Keywords: Helicobacter pylori; Iatrogenic ulcer; Endoscopic resection; Eradication; Medical Research Collaboration Center
Search for
Services
Archives